Article

Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy.

Department of Pathology, Columbia Presbyterian Medical Center, New York, New York, USA.
Modern Pathology (Impact Factor: 6.36). 12/2003; 16(11):1102-8. DOI: 10.1097/01.MP.0000096041.13859.AB
Source: PubMed

ABSTRACT Chemotherapy or chemoradiation is often used in Stage IIIA non-small cell lung carcinoma before surgical resection (neoadjuvant therapy). In reviewing the histopathology of such tumors after resection, the recognition that the pathologic changes are related to prior therapy and the assessment of tumor regression are both of importance. To refine histologic parameters for tumor regression and describe patterns of tumor reaction to therapy, we identified 30 lobectomy or pneumonectomy specimens from 1996-2000 in which neoadjuvant therapy was received before surgical resection. Histologic patterns of treatment-induced tumor regression were analyzed semiquantitatively and included necrosis, fibrosis, mixed inflammatory infiltrate, foamy macrophages, and giant cells. To identify clinical and histologic parameters that correlate with treatment response, the 30 specimens were graded for tumor regression. No correlation was found between tumor regression and age, gender, or type of therapy (chemoradiation versus chemotherapy alone). Squamous cell carcinoma showed a significantly higher rate of response than adenocarcinoma (P =.04), with a significant number of adenocarcinomas in the nonresponder subgroup (P =.05). Tumor size reduction by radiologic assessment, when compared with histologic regression, did not reveal a statistically significant association. However, a positive correlation was found between extent of fibrosis and radiologic estimate of size reduction.

0 Bookmarks
 · 
83 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The potential of (18)F-FDG PET changes was evaluated for prediction of response to concomitant chemoradiotherapy in patients with locally advanced non-small cell lung cancer (NSCLC). For 28 patients, (18)F-FDG PET was performed before treatment, at the end of the second week of treatment, and at 2 wk and 3 mo after the completion of treatment. Standardized uptake value (SUV), maximum SUV, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were obtained. Early metabolic changes were defined as fractional change (ΔTLG) when (18)F-FDG PET at the end of the second week was compared with pretreatment (18)F-FDG PET. In-treatment metabolic changes, as measured by serial (18)F-FDG PET, were correlated with standard criteria of response evaluation of solid tumors by means of CT imaging (Response Evaluation Criteria In Solid Tumors 1.1). Parameters were analyzed for stratification in progression-free survival (PFS). When compared with early metabolic nonresponders, a ΔTLG decrease of 38% or more was associated with a significantly longer PFS (1-y PFS 80% vs. 36%, P = 0.02). Pretreatment TLG was found to be a prognostic factor for PFS. The degree of change in TLG was predictive for response to concomitant chemoradiotherapy as early as the end of the second week into treatment for patients with locally advanced NSCLC. Pretreatment TLG was prognostic for PFS.
    Journal of Nuclear Medicine 07/2013; 54(9). DOI:10.2967/jnumed.112.116921 · 5.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE: Approximately 1/3 of the patients with advanced non-small cell lung cancer (NSCLC) will initially respond to platinum-based chemotherapy, but virtually all tumors will progress (acquired resistance). The remainder will progress during initial treatment (primary resistance). In this study, we test whether the treatment can be improved by inhibiting hepatoma-derived growth factor (HDGF). EXPERIMENTAL DESIGN: Thirteen primary NSCLC hetero-transplant models were used to test four treatment regimens including platinum-based chemotherapy with and without bevacizumab (VEGF neutralizing antibody) or HDGF-H3 (HDGF neutralizing antibody) and chemotherapy with bevacizumab and HDGF-H3. Expression of stem-cell related genes was measured using quantitative RT-PCR and immunohistochemistry. RESULTS: Among 13 primary NSCLC hetero-transplant models, 3 (23%) responded to chemotherapy but all relapsed within 20 days. The residual tumors after response to the chemotherapy exhibited an increased expression in 51 (61%) of 84 genes related with stem-cell proliferation and maintenance, particularly those in Notch and Wnt pathways, suggesting an enrichment for stem-cell populations in the residual tumors. Interestingly, tumors from 2 of the 3 models treated with HDGF-H3, bevacizumab, and chemotherapy combination did not relapse during 6 months of post treatment observation. Importantly, this treatment combination substantially down-regulated expression levels in 57 (68%) of the 84 stem-cell related genes, including 34 (67%) of the 51 genes up-regulated after the chemotherapy. CONCLUSIONS: These data support the hypothesis that cancer stem-cells (CSCs) are a mechanism for chemotherapy resistance and suggest HDGF may be a target for repressing CSCs to prevent relapse of NSCLC sensitive to chemotherapy.
    Clinical Cancer Research 05/2013; 19(13). DOI:10.1158/1078-0432.CCR-12-3478 · 8.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: After neoadjuvant therapy of non-small cell lung cancer, the extent of therapy-induced tumor regression in corresponding resection specimens of primary tumors and lymph nodes represents an independent prognostic factor. In the former tumor area, different sized target-like foci with central necrosis, adjoining narrow foam cell rim, peripheral vascular granulation tissue and transition into a marked scarry fibrosis can be found after neoadjuvant therapy. Morphological changes indicating therapy-induced tumor regression can be graded according to the Bochum regression grading system. Therapy-induced cytomorphological changes do not allow reliable conclusions on the success of the applied neoadjuvant therapy and should not form the basis of cytopathological grading.
    Der Pathologe 10/2014; 35(6). DOI:10.1007/s00292-014-1919-x · 0.64 Impact Factor

Full-text (2 Sources)

Download
20 Downloads
Available from
Jun 26, 2014